Immunexpress
Immunexpress is a molecular diagnostic company dedicated to improving outcomes for patients suspected of sepsis. They develop rapid, immune response-based diagnostic tools that enable early detection and differentiation of sepsis from other systemic inflammations, aiming to reduce mortality, healthcare costs, and improve patient management.
Industries
Nr. of Employees
small (1-50)
Immunexpress
Patents
Treating or inhibiting severe sepsis based on measuring defensin alpha 4 (DEFA4) expression
US-12006548-B2
View DetailsUse of C3AR1 as a biomarker in methods of treating inflammatory response syndromes
US-10975437-B2
View Details
Treating or inhibiting severe sepsis based on measuring defensin alpha 4 (DEFA4) expression
US-12006548-B2
View DetailsUse of C3AR1 as a biomarker in methods of treating inflammatory response syndromes
US-10975437-B2
View DetailsProducts
Rapid host-response sepsis diagnostic (sample-to-answer RT-PCR cartridge)
A cartridge-based, sample-to-answer molecular diagnostic that quantifies host immune-response gene expression from whole blood by RT-PCR to generate a clinical score indicating likelihood of sepsis; designed for use alongside clinical assessment to differentiate infection-positive sepsis from non-infectious systemic inflammation and to assist triage.
Rapid host-response sepsis diagnostic (sample-to-answer RT-PCR cartridge)
A cartridge-based, sample-to-answer molecular diagnostic that quantifies host immune-response gene expression from whole blood by RT-PCR to generate a clinical score indicating likelihood of sepsis; designed for use alongside clinical assessment to differentiate infection-positive sepsis from non-infectious systemic inflammation and to assist triage.
Services
Design and execution of prospective and retrospective multi-site studies, data generation, and publication to validate diagnostic performance in hospital and ICU settings.
In-silico analyses and signature performance modelling using microarray and other transcriptomic datasets to inform assay design and expected clinical discrimination.
Design and execution of prospective and retrospective multi-site studies, data generation, and publication to validate diagnostic performance in hospital and ICU settings.
In-silico analyses and signature performance modelling using microarray and other transcriptomic datasets to inform assay design and expected clinical discrimination.
Expertise Areas
- Molecular diagnostics development
- Host-response biomarker discovery and validation
- Clinical trial design and multi-site validation
- Point-of-care / sample-to-answer assay integration
Key Technologies
- Reverse-transcription quantitative PCR (RT-qPCR)
- Host gene expression profiling
- Cartridge-based sample-to-answer automation
- Whole blood (EDTA) RNA processing
News & Updates
Immunexpress announced a research snapshot presentation of clinical data demonstrating the performance of SeptiCyte® RAPID in adult and pediatric patients with sepsis or systemic inflammation at the SCCM 50th Annual Critical Care Congress.
Immunexpress announced that Dr. Therese Seldon will present data on the utility of SeptiCyte® Lab to aid in the clinical assessment of sepsis at the Next Generation Diagnostics Summit.
Immunexpress launched a rapid molecular diagnostic test, SeptiCyte Rapid, at AMP 2022 that can enable ruling in or out sepsis in one hour.
Immunexpress announced a poster presentation at ECCMID 2023 evaluating SeptiCyte® RAPID as a tool to determine sepsis status in ICU patients, demonstrating its ability to differentiate sepsis from non-sepsis.
Immunexpress announced a research snapshot presentation of clinical data demonstrating the performance of SeptiCyte® RAPID in adult and pediatric patients with sepsis or systemic inflammation at the SCCM 50th Annual Critical Care Congress.
Immunexpress announced that Dr. Therese Seldon will present data on the utility of SeptiCyte® Lab to aid in the clinical assessment of sepsis at the Next Generation Diagnostics Summit.
Immunexpress launched a rapid molecular diagnostic test, SeptiCyte Rapid, at AMP 2022 that can enable ruling in or out sepsis in one hour.
Immunexpress announced a poster presentation at ECCMID 2023 evaluating SeptiCyte® RAPID as a tool to determine sepsis status in ICU patients, demonstrating its ability to differentiate sepsis from non-sepsis.